^

Health

Verisin

, medical expert
Last reviewed: 23.04.2024
Fact-checked
х

All iLive content is medically reviewed or fact checked to ensure as much factual accuracy as possible.

We have strict sourcing guidelines and only link to reputable media sites, academic research institutions and, whenever possible, medically peer reviewed studies. Note that the numbers in parentheses ([1], [2], etc.) are clickable links to these studies.

If you feel that any of our content is inaccurate, out-of-date, or otherwise questionable, please select it and press Ctrl + Enter.

Verisin is used for vertigo (disorders with vestibular character).

Indications Verisina

It is used in people with Meniere's disease, and also for the treatment or prevention of the appearance of dizziness associated with vestibular activity and having a different nature.

Syndromes that cause pain or tinnitus, severe headaches and severe dizziness, vomiting with nausea, and progressive hearing loss.

Release form

The release of the drug substance is made in tablets, in the amount of 10 pieces inside a blister pack. The box contains 3 packs with tablets of 8, 16 and 24 mg.

Pharmacodynamics

Betahistine hydrochloride mainly affects the H1-as well as H3-terminations of histamine in the inner ear, and also on the vestibular nuclei in the region of the central nervous system. The direct agonistic effect on the vascular H1-terminations, and in addition, the indirect effect on the H3-terminations helps to improve microcirculation processes - by relaxing the intense pericapilary sphincters, as well as by stabilizing the level of endolymphatic pressure inside the labyrinth shell. In addition to the above, betahistine increases blood circulation within the basilar arteries.

The drug has a powerful central effect, due to which it can slow down the activity of H3-terminations inside the vestibular neural nuclei. Stabilizes the processes of conduction inside these nuclei in the region of the cerebral trunk.

The clinical symptom of the above effect is a reduction in the intensity and frequency of dizziness, a decrease in ear noise, and an improvement in hearing as it deteriorates.

Pharmacokinetics

The absorption of the active element occurs at high speed; synthesis with plasma protein is weak.

Half-life is about 3-4 hours. The drug is almost completely excreted through the kidneys in the form of a metabolic product (2-pyridylacetic acid) over a period of 24 hours.

Dosing and administration

Take the medicine with or after food. Tablets can not be chewed.

Often, first take 24 mg of substance per day. Later this portion decreases to 8-16 mg per day (as a supportive agent, taking into account the patient's response to therapy). It is necessary to take into account that it is allowed to take no more than 32 mg of medicine per day.

Signs of improvement are often noted from the very beginning of the treatment cycle, and a stable drug effect develops after 14 days of using the drug and then may increase over the course of several months of the treatment course. Therapy has a longer duration (its specific framework is determined separately for each patient).

Use Verisina during pregnancy

It is forbidden to use during lactation or pregnancy, because the information that allows to evaluate the drug activity and the safety of the drug for this group of patients is not enough.

Contraindications

Main contraindications:

  • pheochromocytoma;
  • ulcerative lesions in the gastrointestinal tract;
  • the presence of intolerance to medicinal elements.

Side effects Verisina

Sometimes patients experience vomiting, tremor, nausea, fatigue, headaches, rashes, and paresthesias.

trusted-source[1]

Overdose

Histamine contained in drugs may cause dizziness, tachycardia, headaches, flushing in the face and upper torso, as well as angioedema, bronchial spasms and a decrease in blood pressure.

The patient is required to inject cortisone with epinephrine, and in addition, antihistamine drugs with a rapid type of exposure. If stable hemodynamics is noted, gastric lavage is performed and activated carbon is taken with medications that accelerate the elimination process.

Interactions with other drugs

Antihistamines are betahistine antagonists; Because of this, before using Verisin, their use must be discontinued.

In the case of their combination, they take into account the risk of mutual deterioration of their effectiveness, and in addition, the fact that antihistamine drugs can cause a sedative effect, as well as sleep disorders and anxiety (if they are quickly canceled). Therefore, they must be canceled gradually - over a period of 6 days. If rapid cancellation does occur, it is necessary to additionally prescribe the use of sedative medication for several days.

trusted-source[2], [3]

Storage conditions

Verisin must be maintained at temperature values not exceeding 25 ° C.

trusted-source

Shelf life

Verisin can be used for a 24-month period from the date the pharmaceutical product was manufactured.

trusted-source

Application for children

The use of Verissin in pediatrics (before the onset of the 12th anniversary) is prohibited.

Analogs

Analogues of the substance are the medicines Betadrin, Duellin, Setegis, Naloxon-M, Ferretab, Alex Plus with Talliton, and in addition Relzer, Albarel, Tizertsin and Serdol with Erolina. Also on the list are Vepesid, Gepabene, Grandaxin, NovoSeven with Cardilopin, Vermox with Roxyhexal and Trimetazide with Infukol HES.

Attention!

To simplify the perception of information, this instruction for use of the drug "Verisin" translated and presented in a special form on the basis of the official instructions for medical use of the drug. Before use read the annotation that came directly to medicines.

Description provided for informational purposes and is not a guide to self-healing. The need for this drug, the purpose of the treatment regimen, methods and dose of the drug is determined solely by the attending physician. Self-medication is dangerous for your health.

Translation Disclaimer: For the convenience of users of the iLive portal this article has been translated into the current language, but has not yet been verified by a native speaker who has the necessary qualifications for this. In this regard, we warn you that the translation of this article may be incorrect, may contain lexical, syntactic and grammatical errors.

You are reporting a typo in the following text:
Simply click the "Send typo report" button to complete the report. You can also include a comment.